Reproduction and Fertility is an open-access, peer-reviewed journal
Page URL: https://www.bionews.org.uk/page_155383

Gene therapy benefits seen decades after treatment

22 March 2021
Appeared in BioNews 1088

Healthy immune cells are still forming 18 years after blood stem cell transplantation in patients with faulty immune systems, research has found.

In collaboration with Harvard Medical School, Boston, Massachusetts and Great Ormond Street Hospital, London, researchers at University College London (UCL) monitored five patients affected by SCID-X1 – a severe genetic condition that results in the lack of a functional immune system – who had received gene therapy and were successfully cured. The team analysed patients' blood regularly for 3-18 years to detect which cell types were present in their blood. Although the stem cells transplanted as part of the gene therapy were no longer present, the gene-corrected immune cells, called T-cells, were still forming.

'It has been incorrectly thought for some time that someone needs engineered stem cells in the bone marrow to produce new gene-corrected T-cells.' said co-author Dr Luca Biasco from UCL. 'We spent five years testing our hypothesis from every possible angle and we can now confirm that new T-cells can be still generated for decades even in absence of stem cells.'

Gene therapy is an experimental technique designed to introduce genetic material into cells to compensate for defective genes. It works by first collecting some of the patients' blood-forming stem cells, which generate all types of blood and immune cells. Then by using a carrier, called a vector, the genetically-engineered correct gene is inserted into the DNA of the faulty cells in the laboratory. Finally, the corrected stem cells are re-implanted in the patient, where they start producing a continuous supply of healthy immune cells able to fight infections.

The study showed that while the corrected stem cells were cleared by the body, the five SCID-X1 patients remained healthy and continued generating T-cells for decades after the gene therapy treatment. The British-American team suggested that the human thymus – the organ that makes all blood and immune cells – might work as a long-term store of specialised stem cells, also known as 'progenitor cells', that can generate new T-cells.

'When we initially discovered that newly-engineered T-cells were being actively produced in patients many years after receiving engineered stem cells, we were very excited. We had predicted the existence of the long-term store of cells in the thymus that could turn into T-cells, but now we had the proof.' said Dr Biasco.

Published in Nature Communications, the discovery has important therapeutic implications and 'could be crucial for the development of next-generation therapy and cancer immunotherapy approaches.' said Professor Adrian Thrasher, one of the authors of the study.

The team plans to investigate further in order to improve the safety and effectiveness of this technique.

SOURCES & REFERENCES
Cellular benefits of gene therapy seen decades after treatment
UCL Great Ormond Street Institute of Child Health |  16 March 2021
Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans
Nature Communications |  12 March 2021
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
15 March 2021 - by Dr Yvonne Collins 
Scientific American in partnership with Cellectis, hosted a virtual event to explore genome editing and its use in the clinic. Three pioneers of the field were invited to discuss the early days of genome editing, new technologies and future challenges...
8 March 2021 - by Anna Wernick 
Designer antibodies can alert the immune system to cancerous proteins, slowing tumour growth in mice – three independent studies demonstrate...
14 December 2020 - by Julianna Photopoulos 
Vision improves in both eyes when gene therapy is administered to only one eye, an international team of researchers has found whilst treating a rare form of blindness...
26 October 2020 - by Christina Burke 
Researchers in the US have developed a new CRISPR genome editing approach for making much larger edits to the genome...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.